Benitec Biopharma Inc.
BNTC
$13.59
-$0.305-2.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -89.71% | -1.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -89.71% | -1.61% |
| Cost of Revenue | 97.14% | 98.11% | -- | -1,300.00% | -1,266.67% |
| Gross Profit | -98.19% | -98.90% | 44.00% | 94.92% | 213.21% |
| SG&A Expenses | 56.65% | 27.12% | 9.51% | -3.66% | -10.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.74% | 9.57% | 17.40% | 11.18% | 17.90% |
| Operating Income | -11.05% | -9.97% | -17.87% | -11.54% | -17.97% |
| Income Before Tax | 1.81% | -2.12% | -11.19% | -8.63% | -15.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.81% | -2.12% | -11.19% | -8.63% | -15.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.81% | -2.12% | -11.19% | -8.63% | -15.73% |
| EBIT | -11.05% | -9.97% | -17.87% | -11.54% | -17.97% |
| EBITDA | -11.10% | -10.13% | -18.25% | -11.81% | -18.41% |
| EPS Basic | 72.79% | 55.00% | 52.90% | 58.60% | 60.96% |
| Normalized Basic EPS | 72.71% | 54.48% | 55.02% | 59.76% | 61.96% |
| EPS Diluted | 72.79% | 55.00% | 52.90% | 58.60% | 60.96% |
| Normalized Diluted EPS | 72.71% | 54.48% | 55.02% | 59.76% | 61.96% |
| Average Basic Shares Outstanding | 451.18% | 249.82% | 192.61% | 105.05% | 149.10% |
| Average Diluted Shares Outstanding | 451.18% | 249.82% | 192.61% | 105.05% | 149.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |